PD-1/PD-L1 inhibitors are proven to improve survival in advanced stage NSCLC, and also have activity for SCLC (Horn et al., 2018, Paz-Ares et al., 2019). This evidence concerns the gene CD274 and non-small cell lung carcinoma.